 Jennifer Taylor-Cousar
Concepts (285)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cystic Fibrosis | 89 | 2024 | 965 | 19.310 |
Why?
| | Cystic Fibrosis Transmembrane Conductance Regulator | 58 | 2024 | 288 | 12.700 |
Why?
| | Quinolones | 21 | 2024 | 98 | 8.890 |
Why?
| | Aminophenols | 33 | 2024 | 112 | 8.130 |
Why?
| | Benzodioxoles | 21 | 2024 | 84 | 5.320 |
Why?
| | Chloride Channel Agonists | 19 | 2023 | 58 | 4.300 |
Why?
| | Sinusitis | 7 | 2023 | 175 | 2.990 |
Why?
| | Indoles | 12 | 2024 | 316 | 2.700 |
Why?
| | Aminopyridines | 5 | 2018 | 85 | 2.280 |
Why?
| | Mutation | 33 | 2023 | 3457 | 2.130 |
Why?
| | Membrane Transport Modulators | 3 | 2020 | 7 | 2.080 |
Why?
| | Rhinitis | 5 | 2023 | 129 | 1.930 |
Why?
| | Drug Combinations | 17 | 2022 | 291 | 1.780 |
Why?
| | Pyrazoles | 11 | 2024 | 363 | 1.690 |
Why?
| | Olfaction Disorders | 2 | 2022 | 47 | 1.560 |
Why?
| | Azithromycin | 7 | 2021 | 81 | 1.470 |
Why?
| | Reproductive Health | 7 | 2022 | 68 | 1.310 |
Why?
| | Pyrrolidines | 7 | 2024 | 57 | 1.300 |
Why?
| | Respiratory System Agents | 2 | 2020 | 22 | 1.250 |
Why?
| | Pregnancy Complications | 4 | 2021 | 448 | 1.220 |
Why?
| | Pyridines | 8 | 2024 | 440 | 1.200 |
Why?
| | Humans | 96 | 2024 | 119032 | 1.110 |
Why?
| | Pongo pygmaeus | 2 | 2021 | 7 | 1.040 |
Why?
| | Paranasal Sinuses | 3 | 2023 | 64 | 0.990 |
Why?
| | Pregnancy Rate | 3 | 2021 | 55 | 0.970 |
Why?
| | Pongo | 2 | 2021 | 6 | 0.950 |
Why?
| | Anti-Bacterial Agents | 11 | 2022 | 1517 | 0.900 |
Why?
| | Pregnancy | 14 | 2023 | 5694 | 0.870 |
Why?
| | Adult | 41 | 2023 | 31525 | 0.850 |
Why?
| | Diabetes Mellitus | 2 | 2022 | 945 | 0.800 |
Why?
| | Pseudomonas Infections | 8 | 2022 | 193 | 0.800 |
Why?
| | Infectious Disease Transmission, Patient-to-Professional | 1 | 2020 | 20 | 0.770 |
Why?
| | Ape Diseases | 2 | 2021 | 7 | 0.760 |
Why?
| | Parents | 4 | 2023 | 1212 | 0.750 |
Why?
| | Female | 49 | 2023 | 61588 | 0.740 |
Why?
| | Drug Approval | 2 | 2023 | 77 | 0.740 |
Why?
| | Lung | 9 | 2023 | 3666 | 0.730 |
Why?
| | Compassionate Use Trials | 1 | 2019 | 8 | 0.730 |
Why?
| | Drug Monitoring | 6 | 2020 | 187 | 0.710 |
Why?
| | Precision Medicine | 2 | 2021 | 363 | 0.690 |
Why?
| | Aerosols | 1 | 2020 | 221 | 0.690 |
Why?
| | Sputum | 5 | 2022 | 291 | 0.690 |
Why?
| | Pseudomonas aeruginosa | 9 | 2022 | 305 | 0.680 |
Why?
| | Pregnancy Outcome | 5 | 2021 | 349 | 0.640 |
Why?
| | Forced Expiratory Volume | 11 | 2023 | 520 | 0.620 |
Why?
| | Breast Feeding | 2 | 2022 | 386 | 0.610 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 1 | 2020 | 246 | 0.600 |
Why?
| | Aldehyde Oxidoreductases | 1 | 2017 | 32 | 0.590 |
Why?
| | Prospective Studies | 10 | 2023 | 6477 | 0.590 |
Why?
| | Sexual Health | 3 | 2022 | 46 | 0.570 |
Why?
| | Rifampin | 1 | 2017 | 69 | 0.570 |
Why?
| | Quality of Life | 10 | 2023 | 2369 | 0.560 |
Why?
| | Pongo abelii | 1 | 2016 | 2 | 0.560 |
Why?
| | Glucose Tolerance Test | 1 | 2016 | 368 | 0.530 |
Why?
| | Sildenafil Citrate | 2 | 2014 | 57 | 0.520 |
Why?
| | Glucose Intolerance | 1 | 2016 | 139 | 0.520 |
Why?
| | Treatment Outcome | 13 | 2021 | 9346 | 0.510 |
Why?
| | Bronchiectasis | 1 | 2016 | 105 | 0.500 |
Why?
| | Tobramycin | 5 | 2019 | 50 | 0.500 |
Why?
| | Prenatal Exposure Delayed Effects | 1 | 2020 | 468 | 0.500 |
Why?
| | Leukocyte Elastase | 1 | 2014 | 80 | 0.500 |
Why?
| | Biomedical Research | 1 | 2020 | 612 | 0.500 |
Why?
| | Child | 17 | 2023 | 19137 | 0.490 |
Why?
| | Male | 36 | 2023 | 57818 | 0.470 |
Why?
| | Genetic Therapy | 3 | 2023 | 267 | 0.460 |
Why?
| | Lactation | 3 | 2022 | 160 | 0.420 |
Why?
| | Sweat | 7 | 2021 | 38 | 0.420 |
Why?
| | Chronic Disease | 6 | 2023 | 1637 | 0.400 |
Why?
| | Double-Blind Method | 9 | 2023 | 1687 | 0.390 |
Why?
| | Homozygote | 4 | 2021 | 190 | 0.390 |
Why?
| | Respiratory Function Tests | 5 | 2021 | 526 | 0.380 |
Why?
| | Quinolines | 2 | 2021 | 128 | 0.370 |
Why?
| | Drug Interactions | 4 | 2020 | 352 | 0.360 |
Why?
| | Hypoventilation | 1 | 2009 | 7 | 0.350 |
Why?
| | International Cooperation | 2 | 2020 | 177 | 0.350 |
Why?
| | Adolescent | 17 | 2022 | 18483 | 0.340 |
Why?
| | Respiratory Muscles | 1 | 2009 | 36 | 0.340 |
Why?
| | Parenting | 2 | 2023 | 252 | 0.340 |
Why?
| | ABO Blood-Group System | 1 | 2009 | 35 | 0.340 |
Why?
| | Genotype | 7 | 2023 | 1882 | 0.330 |
Why?
| | Blood Glucose | 2 | 2016 | 1946 | 0.320 |
Why?
| | Tomography, X-Ray Computed | 4 | 2022 | 2436 | 0.320 |
Why?
| | Needs Assessment | 2 | 2020 | 327 | 0.310 |
Why?
| | Young Adult | 14 | 2022 | 10799 | 0.310 |
Why?
| | Chlorides | 7 | 2023 | 137 | 0.310 |
Why?
| | Clinical Trials as Topic | 2 | 2022 | 968 | 0.280 |
Why?
| | Polymorphism, Genetic | 1 | 2009 | 642 | 0.270 |
Why?
| | Surveys and Questionnaires | 3 | 2022 | 4709 | 0.260 |
Why?
| | Alleles | 6 | 2023 | 832 | 0.240 |
Why?
| | Pregnancy, Unplanned | 2 | 2023 | 32 | 0.240 |
Why?
| | C-Reactive Protein | 2 | 2018 | 364 | 0.240 |
Why?
| | Orphan Drug Production | 1 | 2023 | 6 | 0.240 |
Why?
| | Patient Selection | 2 | 2019 | 675 | 0.230 |
Why?
| | Ion Transport | 2 | 2021 | 60 | 0.220 |
Why?
| | Fertility | 1 | 2023 | 135 | 0.220 |
Why?
| | Animals | 9 | 2022 | 33399 | 0.210 |
Why?
| | Epoxide Hydrolases | 1 | 2021 | 9 | 0.210 |
Why?
| | Azabicyclo Compounds | 1 | 2021 | 5 | 0.210 |
Why?
| | Enzyme Activators | 1 | 2021 | 6 | 0.210 |
Why?
| | Observational Studies as Topic | 1 | 2022 | 89 | 0.210 |
Why?
| | Benzoates | 1 | 2021 | 40 | 0.200 |
Why?
| | RNA, Messenger | 3 | 2022 | 2661 | 0.200 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2017 | 1947 | 0.200 |
Why?
| | Multicenter Studies as Topic | 1 | 2022 | 253 | 0.200 |
Why?
| | Men's Health | 1 | 2020 | 8 | 0.200 |
Why?
| | Infertility | 1 | 2021 | 45 | 0.190 |
Why?
| | Disease Progression | 5 | 2020 | 2490 | 0.190 |
Why?
| | Smell | 1 | 2021 | 118 | 0.190 |
Why?
| | Women's Rights | 1 | 2020 | 3 | 0.190 |
Why?
| | Communicable Disease Control | 1 | 2020 | 72 | 0.180 |
Why?
| | Virulence Factors | 2 | 2014 | 140 | 0.180 |
Why?
| | Aztreonam | 2 | 2016 | 8 | 0.180 |
Why?
| | Cataract | 1 | 2022 | 194 | 0.180 |
Why?
| | Patient Reported Outcome Measures | 1 | 2022 | 252 | 0.180 |
Why?
| | Colistin | 1 | 2019 | 10 | 0.180 |
Why?
| | Sexism | 1 | 2020 | 45 | 0.180 |
Why?
| | Neutrophils | 3 | 2016 | 1233 | 0.170 |
Why?
| | Contraception Behavior | 1 | 2020 | 81 | 0.170 |
Why?
| | Asthma | 2 | 2023 | 2159 | 0.170 |
Why?
| | Receptors, Interleukin-8B | 1 | 2018 | 23 | 0.170 |
Why?
| | Medication Therapy Management | 1 | 2020 | 72 | 0.170 |
Why?
| | Contraception | 1 | 2020 | 118 | 0.160 |
Why?
| | Pyrimidines | 1 | 2021 | 382 | 0.160 |
Why?
| | Administration, Oral | 1 | 2020 | 756 | 0.160 |
Why?
| | Severity of Illness Index | 5 | 2021 | 2674 | 0.160 |
Why?
| | HEK293 Cells | 1 | 2020 | 625 | 0.150 |
Why?
| | Cytochrome P-450 CYP3A Inducers | 1 | 2017 | 5 | 0.150 |
Why?
| | Pregnancy, High-Risk | 1 | 2017 | 12 | 0.150 |
Why?
| | Leukocytes | 1 | 2018 | 290 | 0.150 |
Why?
| | Respiratory Tract Infections | 1 | 2021 | 331 | 0.150 |
Why?
| | Machine Learning | 1 | 2020 | 331 | 0.150 |
Why?
| | Risk Assessment | 3 | 2021 | 3057 | 0.150 |
Why?
| | Biological Availability | 1 | 2017 | 126 | 0.150 |
Why?
| | Biphenyl Compounds | 1 | 2017 | 52 | 0.150 |
Why?
| | Prognosis | 2 | 2022 | 3443 | 0.140 |
Why?
| | Methicillin-Resistant Staphylococcus aureus | 1 | 2019 | 190 | 0.140 |
Why?
| | Research | 1 | 2020 | 411 | 0.140 |
Why?
| | Risk Adjustment | 1 | 2017 | 79 | 0.140 |
Why?
| | Gene Expression Profiling | 3 | 2018 | 1597 | 0.140 |
Why?
| | Recovery of Function | 1 | 2020 | 604 | 0.140 |
Why?
| | Pilot Projects | 2 | 2020 | 1420 | 0.140 |
Why?
| | Infant, Newborn | 3 | 2023 | 5256 | 0.140 |
Why?
| | Pharmacogenetics | 1 | 2017 | 151 | 0.140 |
Why?
| | Albuterol | 1 | 2016 | 104 | 0.130 |
Why?
| | Middle Aged | 9 | 2021 | 27627 | 0.130 |
Why?
| | Interferons | 1 | 2016 | 151 | 0.130 |
Why?
| | Epithelial Cells | 2 | 2020 | 963 | 0.130 |
Why?
| | Adrenal Cortex Hormones | 1 | 2018 | 521 | 0.130 |
Why?
| | Staphylococcal Infections | 1 | 2019 | 346 | 0.130 |
Why?
| | Diabetes Complications | 1 | 2016 | 219 | 0.130 |
Why?
| | Phosphodiesterase 5 Inhibitors | 1 | 2014 | 36 | 0.130 |
Why?
| | Metalloproteases | 1 | 2014 | 38 | 0.120 |
Why?
| | DNA Mutational Analysis | 1 | 2015 | 381 | 0.120 |
Why?
| | Bronchodilator Agents | 1 | 2016 | 253 | 0.120 |
Why?
| | Biomarkers | 4 | 2022 | 3590 | 0.120 |
Why?
| | Quorum Sensing | 1 | 2014 | 72 | 0.120 |
Why?
| | Genetic Predisposition to Disease | 2 | 2015 | 2275 | 0.120 |
Why?
| | Health Services Accessibility | 1 | 2019 | 781 | 0.110 |
Why?
| | Administration, Inhalation | 3 | 2022 | 656 | 0.110 |
Why?
| | Wound Infection | 1 | 2013 | 31 | 0.110 |
Why?
| | Neutrophil Activation | 1 | 2013 | 100 | 0.110 |
Why?
| | Mycobacterium Infections | 1 | 2013 | 61 | 0.110 |
Why?
| | Blood Glucose Self-Monitoring | 1 | 2016 | 534 | 0.110 |
Why?
| | Cellular Structures | 1 | 2011 | 3 | 0.100 |
Why?
| | Retrospective Studies | 8 | 2023 | 12990 | 0.100 |
Why?
| | Comorbidity | 1 | 2016 | 1527 | 0.100 |
Why?
| | Mycobacterium | 1 | 2013 | 103 | 0.100 |
Why?
| | Risk Factors | 3 | 2020 | 9003 | 0.100 |
Why?
| | Drug Therapy, Combination | 3 | 2021 | 965 | 0.100 |
Why?
| | Microbial Viability | 1 | 2011 | 81 | 0.100 |
Why?
| | Extracellular Space | 1 | 2011 | 127 | 0.100 |
Why?
| | Patient Admission | 1 | 2012 | 177 | 0.100 |
Why?
| | Endoscopy | 2 | 2023 | 272 | 0.090 |
Why?
| | Leukocytes, Mononuclear | 1 | 2013 | 509 | 0.090 |
Why?
| | Survival Rate | 2 | 2018 | 1720 | 0.090 |
Why?
| | Body Mass Index | 1 | 2017 | 2092 | 0.090 |
Why?
| | Mass Screening | 1 | 2016 | 1052 | 0.090 |
Why?
| | Cardiovascular Diseases | 1 | 2021 | 1802 | 0.090 |
Why?
| | Burns | 1 | 2013 | 247 | 0.090 |
Why?
| | Blood Group Antigens | 1 | 2009 | 16 | 0.090 |
Why?
| | Inflammation | 2 | 2022 | 2571 | 0.080 |
Why?
| | Mucus | 1 | 2009 | 54 | 0.080 |
Why?
| | Inpatients | 1 | 2012 | 389 | 0.080 |
Why?
| | ADP Ribose Transferases | 1 | 2007 | 10 | 0.080 |
Why?
| | Exotoxins | 1 | 2007 | 15 | 0.080 |
Why?
| | United States | 3 | 2023 | 12557 | 0.080 |
Why?
| | Furin | 1 | 2007 | 13 | 0.080 |
Why?
| | Oxygen Inhalation Therapy | 1 | 2009 | 124 | 0.080 |
Why?
| | Sexual Behavior | 2 | 2022 | 437 | 0.080 |
Why?
| | 3',5'-Cyclic-GMP Phosphodiesterases | 1 | 2007 | 17 | 0.080 |
Why?
| | Aged | 4 | 2023 | 19661 | 0.080 |
Why?
| | Phenotype | 1 | 2015 | 3004 | 0.070 |
Why?
| | Cyclic GMP | 1 | 2007 | 109 | 0.070 |
Why?
| | Bacterial Toxins | 1 | 2007 | 106 | 0.070 |
Why?
| | Survivors | 1 | 2010 | 418 | 0.070 |
Why?
| | Gene Expression Regulation | 1 | 2016 | 2446 | 0.070 |
Why?
| | Sulfones | 1 | 2007 | 98 | 0.070 |
Why?
| | Respiratory System | 1 | 2007 | 141 | 0.070 |
Why?
| | Respiratory Mucosa | 1 | 2007 | 254 | 0.070 |
Why?
| | Respiration, Artificial | 1 | 2009 | 545 | 0.070 |
Why?
| | Piperazines | 1 | 2007 | 316 | 0.060 |
Why?
| | Logistic Models | 2 | 2019 | 1901 | 0.060 |
Why?
| | Nose | 1 | 2023 | 58 | 0.060 |
Why?
| | Cell Separation | 2 | 2016 | 296 | 0.060 |
Why?
| | Deoxyribonuclease I | 1 | 2022 | 36 | 0.060 |
Why?
| | Rare Diseases | 1 | 2023 | 113 | 0.050 |
Why?
| | Saline Solution, Hypertonic | 1 | 2022 | 56 | 0.050 |
Why?
| | Sex Education | 1 | 2022 | 31 | 0.050 |
Why?
| | Hot Flashes | 1 | 2023 | 72 | 0.050 |
Why?
| | Microbial Sensitivity Tests | 2 | 2014 | 302 | 0.050 |
Why?
| | Contraceptive Agents | 1 | 2022 | 57 | 0.050 |
Why?
| | Biofilms | 2 | 2014 | 231 | 0.050 |
Why?
| | Reproductive Techniques, Assisted | 1 | 2021 | 33 | 0.050 |
Why?
| | Preconception Care | 1 | 2021 | 28 | 0.050 |
Why?
| | Genetic Counseling | 1 | 2021 | 66 | 0.050 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2009 | 2062 | 0.050 |
Why?
| | Attitude | 1 | 2022 | 231 | 0.050 |
Why?
| | Longevity | 1 | 2021 | 151 | 0.050 |
Why?
| | Contraceptives, Oral, Hormonal | 1 | 2020 | 23 | 0.050 |
Why?
| | Menopause | 1 | 2023 | 266 | 0.050 |
Why?
| | Ambulatory Care | 1 | 2023 | 482 | 0.040 |
Why?
| | Condoms | 1 | 2020 | 110 | 0.040 |
Why?
| | Tetraspanin 30 | 1 | 2018 | 9 | 0.040 |
Why?
| | Sequence Analysis, DNA | 1 | 2022 | 755 | 0.040 |
Why?
| | Administration, Intravenous | 1 | 2019 | 136 | 0.040 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2012 | 2179 | 0.040 |
Why?
| | Genetic Testing | 1 | 2021 | 389 | 0.040 |
Why?
| | British Columbia | 1 | 2018 | 17 | 0.040 |
Why?
| | Ecosystem | 1 | 2023 | 555 | 0.040 |
Why?
| | Case-Control Studies | 2 | 2016 | 3173 | 0.040 |
Why?
| | Registries | 2 | 2020 | 1810 | 0.040 |
Why?
| | trans-Golgi Network | 2 | 2007 | 11 | 0.040 |
Why?
| | Morbidity | 1 | 2018 | 296 | 0.040 |
Why?
| | Gene Deletion | 1 | 2018 | 361 | 0.040 |
Why?
| | Nitric Oxide Synthase Type II | 2 | 2007 | 165 | 0.040 |
Why?
| | Drug Administration Routes | 1 | 2016 | 42 | 0.040 |
Why?
| | Leadership | 1 | 2020 | 311 | 0.040 |
Why?
| | Genetic Variation | 1 | 2021 | 926 | 0.030 |
Why?
| | Cells, Cultured | 2 | 2018 | 4081 | 0.030 |
Why?
| | Depression | 1 | 2024 | 1137 | 0.030 |
Why?
| | Interferon-alpha | 1 | 2016 | 191 | 0.030 |
Why?
| | Colorado | 2 | 2018 | 4196 | 0.030 |
Why?
| | Drug Resistance, Multiple, Bacterial | 1 | 2014 | 63 | 0.030 |
Why?
| | Kaplan-Meier Estimate | 1 | 2016 | 842 | 0.030 |
Why?
| | Rats | 1 | 2022 | 5394 | 0.030 |
Why?
| | Medication Adherence | 1 | 2018 | 556 | 0.030 |
Why?
| | Odds Ratio | 1 | 2016 | 996 | 0.030 |
Why?
| | Cohort Studies | 1 | 2023 | 5117 | 0.030 |
Why?
| | Ciprofloxacin | 1 | 2013 | 24 | 0.030 |
Why?
| | Survival Analysis | 1 | 2016 | 1267 | 0.030 |
Why?
| | Multivariate Analysis | 1 | 2016 | 1474 | 0.030 |
Why?
| | Superoxides | 1 | 2013 | 221 | 0.030 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2013 | 333 | 0.030 |
Why?
| | Drug Synergism | 1 | 2013 | 339 | 0.030 |
Why?
| | Suspensions | 1 | 2011 | 30 | 0.030 |
Why?
| | Cell Line | 2 | 2007 | 2707 | 0.030 |
Why?
| | Enteral Nutrition | 1 | 2012 | 172 | 0.020 |
Why?
| | Cell Adhesion | 1 | 2011 | 443 | 0.020 |
Why?
| | Insulin Infusion Systems | 1 | 2012 | 306 | 0.020 |
Why?
| | Aged, 80 and over | 1 | 2021 | 6562 | 0.020 |
Why?
| | Age Distribution | 1 | 2010 | 362 | 0.020 |
Why?
| | Sex Distribution | 1 | 2010 | 351 | 0.020 |
Why?
| | Follow-Up Studies | 1 | 2018 | 4596 | 0.020 |
Why?
| | Child, Preschool | 1 | 2023 | 9493 | 0.020 |
Why?
| | Age of Onset | 1 | 2010 | 467 | 0.020 |
Why?
| | Predictive Value of Tests | 1 | 2013 | 1868 | 0.020 |
Why?
| | Epithelial Sodium Channels | 1 | 2007 | 12 | 0.020 |
Why?
| | Feedback, Physiological | 1 | 2007 | 75 | 0.020 |
Why?
| | Cyclic Nucleotide Phosphodiesterases, Type 5 | 1 | 2007 | 22 | 0.020 |
Why?
| | Guanylate Cyclase | 1 | 2007 | 36 | 0.020 |
Why?
| | Time Factors | 1 | 2018 | 6414 | 0.020 |
Why?
| | Sodium | 1 | 2007 | 200 | 0.020 |
Why?
| | Purines | 1 | 2007 | 161 | 0.020 |
Why?
| | Hydrogen-Ion Concentration | 1 | 2007 | 536 | 0.020 |
Why?
| | In Vitro Techniques | 1 | 2007 | 1096 | 0.020 |
Why?
| | Transforming Growth Factor beta | 1 | 2007 | 462 | 0.020 |
Why?
| | Hypoglycemic Agents | 1 | 2012 | 1035 | 0.020 |
Why?
| | Patient Acceptance of Health Care | 1 | 2010 | 687 | 0.020 |
Why?
| | Mice | 2 | 2013 | 15528 | 0.010 |
Why?
| | Disease Models, Animal | 1 | 2013 | 3730 | 0.010 |
Why?
| | Insulin | 1 | 2012 | 2170 | 0.010 |
Why?
| | Mice, Transgenic | 1 | 2007 | 2025 | 0.010 |
Why?
| | Nitric Oxide | 1 | 2007 | 893 | 0.010 |
Why?
| | Macrophages | 1 | 2007 | 1324 | 0.010 |
Why?
| | Signal Transduction | 1 | 2007 | 4713 | 0.010 |
Why?
|
|
Taylor-Cousar's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|